Inhibikase Therapeutics Reports Results from Phase 2 201 Trial for Risvodetinib
On January 29, 2025, Inhibikase Therapeutics, Inc. (NYSE:IKT) disclosed findings from the Phase 2 201 trial (the “201 Trial”) evaluating risvodetinib, a selective inhibitor of non-receptor Abelson Tyrosine Kinases, in untreated Parkinson’s disease. The 201 Trial involved 126 individuals with untreated Parkinson’s disease who were, on average, 14 months post-diagnosis. Participants received doses of 50 […]
More Stories
Know about Disney’s Hexed: Release Date and Trailer
The teaser for the upcoming Disney film, Hexed, is out. Want to know more? Keep reading. Fawn Veerasunthorn, the creator...
Restaurant Fit-Out Planning Tips for Comfort, Flow and Durability
A restaurant fit-out is really juggling two jobs at the same time. It has to make guests feel like they’ve...
How to Choose the Perfect Dining Table for Your Home Layout
A dining table ends up being more than a table, doesn’t it. Meals happen there, sure, but that’s barely the...
What is Snapchat Planet Order? Meaning, Origin, and More Details
Snapchat is one of the most widely used social media platforms. It stands neck to neck with other popular social...
Is The Amazing Digital Circus Renewed? Know about its Release Date
Are you also a fan of adult anime shows? Good news, everyone’s favourite fantasy drama, The Amazing Digital Circus, aka...
Tex Mex Motors Season 3 Updates and Renewal Details
The 2023 premiere series, Tex Mex Motors, is a reality TV show. The series has 2 seasons with episodes showing...